Registration Dossier

Administrative data

Link to relevant study record(s)

Description of key information

No specific study has been performed on the absorption/distribution/metabolism/excretion (ADME) of 3-PPB. However, data are currently available from in vivo toxicology studies performed with this substance and analogue substances. Studies on the ADME of analogue substances, benzyl benzoate, benzyl alcohol, phenylethyl alcohol, benzoic acid are also used to support the registration of 3-PPB.

Key value for chemical safety assessment

Bioaccumulation potential:
no bioaccumulation potential
Absorption rate - oral (%):
100
Absorption rate - dermal (%):
100
Absorption rate - inhalation (%):
100

Additional information

All evidences presented in the report attached below ( TK Assessment_3-PPB_20150128_Final) support a rapid absorption, biotransformation, and excretion of these substances in the urine. 3-phenylpropyl benzoate is expected to rapidly hydrolyse into 3-phenylpropanol and benzoic acid in animal tissues and predominantly in the liver. 3-Phenylpropanol may subsequently be oxidised to 3-phenylpropanoic acid (PPA) by the liver ADH and ALD. PPA is then expected to be oxidised via the hepatic beta-oxidation pathway in hepatic mitochondria leading to the formation of benzoyl CoA. Benzoyl CoA then formed from these reactions may be conjugated with glycine and excreted as hippuric acid or may be hydrolysed to yield free benzoic acid which can also then be excreted. Similarly, benzoic acid is metabolised in the liver by conjugation with glycine, resulting in the formation of hippuric acid. Distribution of the parent compound or metabolites is expected to be wide into most major organs but to be transient as evidenced by extent of its metabolism and excretion. It is concluded that, like benzyl benzoate, 3-PPB may be expected to be absorbed and metabolised to more polar substances which do not bioaccumulate but are rapidly excreted mainly via urine .